|

Apatinib Mesylate Clinical Trials

9 actively recruiting trials

No change since May 2026

Also known as: apatinib

Pipeline

Phase 2: 3Phase 3: 3Phase 1/2: 1

Top Sponsors

  • Xiangya Hospital of Central South University1
  • The First Affiliated Hospital with Nanjing Medical University1
  • The First Affiliated Hospital of Xiamen University1
  • The First Affiliated Hospital of Bengbu Medical University1
  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1

Indications

Other9 trials

A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer
Phase 2
A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2
Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC
Phase 2
Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer
Phase 1/2
Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST
N/A
Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults
N/A
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
Phase 3
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
Phase 3
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.